Form 8-K Lucid Diagnostics Inc. For: Aug 12

Go back to Form 8-K Lucid Diagnostics Inc. For: Aug 12

Cantor Fitzgerald Positive on Lucid Diagnostics Inc (LUCD) Following Earnings

August 13, 2024 2:57 PM UTC

Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating and $3.00 price target on Lucid Diagnostics Inc (NASDAQ: LUCD).

The analyst comments "We reiterate our Overweight rating and 12-month price target of $3.00 on Lucid Diagnostics' (LUCD) shares following the company reporting 2Q24 operating results and providing... More

Needham Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD)

August 12, 2024 4:47 PM UTC

Needham analyst Mike Matson reiterated a Buy rating and $2.50 price target on Lucid Diagnostics Inc (NASDAQ: LUCD).

The analyst comments "In 2Q24, EsoGuard test volume grew 30% sequentially and 43% Y/Y to 3,147. LUCD missed consensus revenue in 2Q24 and we note that LUCD has... More